Company / Return on Equity (ROE)
Amphstar Pharmaceuticals, Inc. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
12.4%
FY2025
5-year range
12.4% / 21.8%
FY2021-FY2025
Trend
-42.9%
vs FY2024
Sector context
#33 of 190
Health Care
What the data says
Amphstar Pharmaceuticals, Inc.'s return on equity (roe) of 12.4% is higher than 83% of companies in the Health Care sector (FY2025). Return on Equity (ROE) has fluctuated over the past 10 years, ranging from -1.7% in FY2018 to 21.8% in FY2024.
Based on SEC 10-K filings.
12.4% in FY2025 with a 5-year CAGR of +12.1%. Top quartile in the Health Care sector.
Declined from 21.5% to 12.4% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -4.9pp
- 5-Year Change
- +12.1pp
- 10-Year Change
- -
Sector benchmark
+124.7% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 42.9% year-over-year.
- Currently 62.8pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2024.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 12.4% | -42.9% |
| FY2024 | 21.8% | +1.3% |
| FY2023 | 21.5% | +24.4% |
| FY2022 | 17.3% | +24.0% |
| FY2021 | 13.9% | +3882.9% |
| FY2020 | 0.4% | -97.3% |
| FY2019 | 12.8% | +841.6% |
| FY2018 | -1.7% | -258.7% |
| FY2017 | 1.1% | -63.4% |
| FY2016 | 3.0% | +417.0% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026